MX2020005841A - Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6. - Google Patents

Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.

Info

Publication number
MX2020005841A
MX2020005841A MX2020005841A MX2020005841A MX2020005841A MX 2020005841 A MX2020005841 A MX 2020005841A MX 2020005841 A MX2020005841 A MX 2020005841A MX 2020005841 A MX2020005841 A MX 2020005841A MX 2020005841 A MX2020005841 A MX 2020005841A
Authority
MX
Mexico
Prior art keywords
inhibitors
histone deacetylase
oxadiazole derivatives
compounds
relates
Prior art date
Application number
MX2020005841A
Other languages
English (en)
Inventor
González Elena Carceller
Solana Jorge Salas
Muñoz Alberto Ortega
Original Assignee
Oryzon Genomics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics Sa filed Critical Oryzon Genomics Sa
Publication of MX2020005841A publication Critical patent/MX2020005841A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos de la Fórmula (I) como se describe en la presente, útiles como inhibidores de histona-desacetilasa 6 (HDAC6). La invención también se refiere a composiciones farmacéuticas que comprenden estos compuestos y a su uso en terapia.
MX2020005841A 2017-12-05 2018-12-05 Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6. MX2020005841A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382835 2017-12-05
EP18382562 2018-07-26
PCT/EP2018/083655 WO2019110663A1 (en) 2017-12-05 2018-12-05 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors

Publications (1)

Publication Number Publication Date
MX2020005841A true MX2020005841A (es) 2020-09-07

Family

ID=64556931

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005841A MX2020005841A (es) 2017-12-05 2018-12-05 Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.

Country Status (13)

Country Link
US (2) US20200339569A1 (es)
EP (1) EP3720851A1 (es)
JP (1) JP7369458B2 (es)
KR (1) KR102755032B1 (es)
CN (1) CN111406054B (es)
AU (1) AU2018379321B2 (es)
CA (1) CA3083061A1 (es)
IL (1) IL274973B2 (es)
MX (1) MX2020005841A (es)
PH (1) PH12020550698A1 (es)
SG (1) SG11202005254RA (es)
WO (1) WO2019110663A1 (es)
ZA (1) ZA202004023B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
MX2020005841A (es) 2017-12-05 2020-09-07 Oryzon Genomics Sa Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１阻害剤
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
CN114206868B (zh) * 2019-06-06 2025-02-25 奥莱松基因组股份有限公司 作为hdac6抑制剂的3-(2-(杂芳基)-吡啶-4-基)-5-(三氟甲基)-1,2,4-噁二唑衍生物
CN115443329A (zh) 2019-06-27 2022-12-06 乔治华盛顿大学国会特许非营利公司 Hdac6激活的巨噬细胞、其组合物及用途
CN114727974A (zh) 2019-07-30 2022-07-08 艾科尼佐治疗股份有限公司 Hdac6抑制剂及其用途
KR20220119653A (ko) 2019-12-20 2022-08-30 테나야 테라퓨틱스, 인코포레이티드 플루오로알킬-옥사디아졸 및 이의 용도
KR102537616B1 (ko) 2020-02-25 2023-05-26 주식회사 종근당 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
KR102537615B1 (ko) 2020-02-25 2023-05-30 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
KR102576148B1 (ko) * 2020-04-13 2023-09-07 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
KR102685058B1 (ko) 2020-09-02 2024-07-15 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 새로운 구조의 화합물 및 이를 포함하는 약제학적 조성물
WO2022169985A1 (en) 2021-02-03 2022-08-11 Eikonizo Therapeutics, Inc. Hdac6 inhibitors and uses thereof
EP4326263A1 (en) 2021-04-23 2024-02-28 Tenaya Therapeutics, Inc. Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef
AU2023250964A1 (en) 2022-04-08 2024-11-07 Eikonizo Therapeutics, Inc. Oxadiazole hdac6 inhibitors and uses thereof
WO2025215092A1 (en) 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101618B2 (en) * 2005-04-06 2012-01-24 Msd K.K. 1,4-substituted piperazine derivatives
US20100136024A1 (en) * 2008-11-14 2010-06-03 Bartels Stephen P Selective Inhibition of Histone Deacetylase 6 for Ocular Neuroprotection or for Treatment or Control of Glaucoma
NZ610225A (en) 2010-11-16 2015-08-28 Acetylon Pharmaceuticals Inc Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
WO2013066839A2 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
CA2856334A1 (en) 2011-11-28 2013-06-06 Christina Hebach Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
EP3187497A4 (en) 2014-08-26 2018-02-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
US10357484B2 (en) 2015-07-17 2019-07-23 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN108026088B (zh) 2015-07-17 2021-02-12 武田药品工业株式会社 用作hdac抑制剂的噁二唑衍生物
WO2017033946A1 (ja) 2015-08-25 2017-03-02 武田薬品工業株式会社 複素環化合物
JP6970680B2 (ja) 2016-03-15 2021-11-24 セルジーン クオンティセル リサーチ，インク． ヒストンデメチラーゼ阻害剤
WO2017222950A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
EP3475275B1 (en) 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2017222952A1 (en) 2016-06-23 2017-12-28 Merck Sharp & Dohme Corp. 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
WO2018118781A1 (en) 2016-12-20 2018-06-28 Fmc Corporation Fungicidal oxadiazoles
MX2020005841A (es) 2017-12-05 2020-09-07 Oryzon Genomics Sa Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
CN114206868B (zh) 2019-06-06 2025-02-25 奥莱松基因组股份有限公司 作为hdac6抑制剂的3-(2-(杂芳基)-吡啶-4-基)-5-(三氟甲基)-1,2,4-噁二唑衍生物

Also Published As

Publication number Publication date
US12668591B2 (en) 2026-06-30
KR20200097294A (ko) 2020-08-18
JP2021505684A (ja) 2021-02-18
CN111406054A (zh) 2020-07-10
RU2020121391A (ru) 2022-01-10
ZA202004023B (en) 2025-09-25
SG11202005254RA (en) 2020-07-29
IL274973B1 (en) 2024-03-01
BR112020010534A2 (pt) 2020-10-20
US20230026909A1 (en) 2023-01-26
RU2020121391A3 (es) 2022-01-20
JP7369458B2 (ja) 2023-10-26
PH12020550698A1 (en) 2021-04-12
IL274973B2 (en) 2024-07-01
EP3720851A1 (en) 2020-10-14
AU2018379321A1 (en) 2020-06-11
US20200339569A1 (en) 2020-10-29
KR102755032B1 (ko) 2025-01-20
AU2018379321B2 (en) 2024-05-16
CA3083061A1 (en) 2019-06-13
CN111406054B (zh) 2024-01-02
WO2019110663A1 (en) 2019-06-13
IL274973A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
ZA202004023B (en) 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
CR20200312A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
BR112015023399A8 (pt) inibidores de hdac, seu uso e composição farmacêutica
MX371050B (es) Compuestos para tratar atrofia muscular espinal.
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
BR112017023710A2 (pt) inibidores de histona deacetilase e composições e métodos de uso dos mesmos
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
MX384798B (es) Piridinona dicarboxamida para uso como inhibidores de bromodominio.
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
MX2019007571A (es) Polimorfos.
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
ECSP20023626A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
EA201890906A1 (ru) ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.
MX2020006016A (es) Polimorfos.
MX2019012522A (es) Compuestos y metodos terapeuticos.